rcc panel reacts to long-term follow-up from checkmate 214
Published 6 months ago • 146 plays • Length 7:28Download video MP4
Download video MP3
Similar videos
-
18:04
panel shares thoughts on rcc data: checkmate 914, 214 and imdc selection criteria
-
5:05
checkmate 9er: what is the impact for rcc?
-
1:54
checkmate 214 trial in rcc updates
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
4:23
first-line therapy options for rcc: lessons from checkmate 214 and keynote-427
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
13:45
rcc panel reacts to litespark-005 data presented at esmo 2023
-
5:50
checkmate 214: long-term survival implications, treatment ramifications for favorable-risk patients
-
8:56
talapro-2: phase 3 results of talazoparib plus enzalutamide for mcrpc
-
56:59
renal cell carcinoma
-
5:09
recent advances in treating advanced kidney cancer
-
9:00
checkmate 214, keynote-564, and updates in treatment approaches to nccrcc
-
1:21
dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
-
7:18
who is the appropriate rcc patient to receive combination ipilimumab/nivolumab?
-
0:41
#adjuvant #pembrolizumab for #rcc #kidneycancer #cancertreatment #cancer
-
11:58
checkmate 214: nivolumab ipilimumab or sunitinib in patients with advanced renal cell carcinoma
-
2:38
checkmate 9er: cabo-nivo superior to sunitinib in extended follow-up results
-
1:42:43
experts discuss the latest #rcc updates from #onscongress - https://bit.ly/3l3pazu
-
5:10
checkmate 214: patterns of progression with nivolumab plus ipilimumab versus sunitinib for rcc
-
6:26
session 5: nivolumab cabozantinib vs sunitinib for advanced rcc | checkmate9er & checkmate214
-
50:51
how to choose the right combo therapy - dr geynisman - 11/17/22